Flevoziekenhuis Stichting

Almere 39 trials 19 recruiting

39 Registered trials

19 Currently recruiting

Organisation

Flevoziekenhuis Stichting

Location

Almere, Netherlands

Identifier

ORG-100044113

Address

Hospitaalweg 1, 1315 RA, Netherlands

Departments

Dermatologie
Endocrinologie
Gynaecologic oncology
Gynaecology
Hematology
ICU
Internal medicine
interne geneeskunde
Inwendige geneeskunde
medical oncology
Medische Oncologie
N/A
Neurologie
neurology
Obstetrics & Gynecology
Oncologie
Oncology
Ophthalmology
Pulmonary Medicine
Reproductive medicine and gynecology
Surgery

Clinical trials at this site (39)

Search interface

SAFEST Not authorised

2022-502059-79-00 Ischemic stroke or transient ischemic attack 6
ATLAS trial Pending

2024-517233-40-00 Perianal abscess 6
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Pre… Recruiting

2025-524366-21-00 treatment-naive Chronic Lymphocytic Leukemia 5 2026-04-29
T3-4-Hypo trial Recruiting

2024-513883-24-00 Hypothyroidism Triiodothyronine Quality of Life Persist 5 2025-11-02
A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision fo… Recruiting

2024-517410-15-01 Rectal cancer 5 2025-01-14
A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting

2022-502548-12-00 marginal zone lymphoma 5 2023-09-28
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax P… Recruiting

2024-517131-52-00 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small 5 2025-11-03
Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study) Recruiting

2024-519354-36-00 Polycystic ovary syndrome (PCOS) 6 2025-08-01
StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial Recruiting

2024-517343-31-00 Ischemic stroke and transient ischemic attack 6 2025-04-11
Ulipristal versus surgery for symptomatic uterine fibroids Recruiting

2024-512602-26-00 Uterine fibroids 6 2024-12-02
PreVent-ACaLL Recruiting

2024-511072-33-00 Chronic Lymphocytic Leukemia 4 2024-06-12
PEPPER-trial Recruiting

2023-507763-18-01 Placenta previa, preterm birth 6 2024-05-21
FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting

2023-508586-33-00 multiple myeloma 5 2024-05-14
VulVaccin study Recruiting

2023-506792-94-00 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSI 11 2024-03-04
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting

2023-508389-13-00 Combined endpoint of all-cause mortality, kidney failur 5 2022-11-08
Prevention of opioid-induced constipation in patients with advanced cancer. Recruiting

2023-509462-38-00 Patients with advanced cancer. 11 2022-10-25
The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2… Recruiting

2024-513797-22-00 HER2 positive esophageal adenocarcinoma 5 2022-03-09
Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial Recruiting

2024-513314-35-00 Adenocarcinoma of the Colon or rectosigmoid (considered 4 2017-01-20
First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in… Ended

2022-502808-72-00 Chronic Lymphocytic Leukemia 4 2024-09-11
MAD Ended

2024-516379-34-00 Myopia 6 2024-08-02
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) Ended

2024-513105-31-00 Multiple Sclerosis 6 2024-07-30
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-… Ended

2022-502446-27-00 Relapsed or Refractory Myeloma 5 2024-02-26